Tumor stroma-immune interactions shape the immunosuppressive microenvironment and predict response to neoadjuvant chemoradiotherapy plus immunotherapy in rectal cancer
Journal for ImmunoTherapy of Cancer · 2026-08 · 14 (8) · e015376
DOI: 10.1136/jitc-2026-015376 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 03.08.2026. Verfasst von Qianyu Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Peking Union Medical College Hospital, Beijing, China. Hauptthemen laut MEDLINE: Chemoradiotherapy, Immunotherapy, Neoadjuvant Therapy, Rectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The tumor microenvironment, particularly the tumor stroma, plays a critical role in tumor progression, immune evasion, and therapeutic resistance. However, its interaction with the immune landscape in rectal cancer (RC) remains incompletely understood. This study aimed to comprehensively characterize the stromal-immune ecosystem associated with the tumor stroma ratio (TSR) in RC and to evaluate its clinical and therapeutic relevance.
Methods
We analyzed a multicenter cohort of 498 patients with treatment-naïve RC in whom TSR was assessed on H&E-stained sections. Integrative multi-omics analyses were performed, including bulk RNA sequencing (n=118) and single-cell RNA/T-cell receptor (TCR) sequencing (n=10). Key findings were validated by immunohistochemistry (n=114) and multiplex immunofluorescence (n=20). Survival analyses and statistical comparisons were conducted to evaluate clinical associations and treatment responses.
Results
High TSR was an independent predictor of unfavorable disease-free survival and cancer-specific survival and was associated with aggressive clinicopathological features. Single-cell analyses revealed that TSR-high tumors exhibited a profoundly immunosuppressive microenvironment, characterized by clonally expanded terminally exhausted CD8 + T cells (CD8 + Tex-CXCL13) and activated CD4 + regulatory T cells (CD4 + Treg-TNFRSF4). Two LRRC15 + cancer-associated fibroblast (CAF) subsets (mCAF-CTHRC1 and mCAF-FAP) were enriched in TSR-high tumors. Among them, mCAF-CTHRC1 was associated with increased Treg abundance and activation features, with predicted interactions with CD4 + Treg-TNFRSF4 cells through the LGALS9–CD44 signaling axis. In addition, SPP1-expressing monocytes (Mon-SPP1) and malignant epithelial cells were prominent in TSR-high tumors and showed a predicted SPP1–CD44 interaction with T-cell subsets, suggesting potential involvement in immunosuppressive stromal-immune interactions. In patients receiving neoadjuvant therapy, pretreatment TSR-low tumors showed improved pathological response and survival outcomes compared with TSR-high tumors. In the neoadjuvant chemoradiotherapy plus immunotherapy cohort, TSR-low tumors were associated with a significantly higher major pathological response rate, whereas pathological complete response showed a non-significant trend in the same direction.
Conclusions
High TSR identifies a clinically aggressive subtype of RC characterized by a profoundly immunosuppressive stromal-immune ecosystem enriched for exhausted T cells, immunosuppressive CAF programs, and SPP1-associated stromal-myeloid interactions. These findings highlight LGALS9−, LRRC15−, and SPP1-related stromal-immune pathways as candidate stromal-immune therapeutic vulnerabilities that warrant further mechanistic and preclinical validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Peking Union Medical College Hospital, Beijing, China.
- The Seventh Medical Center, Chinese PLA General Hospital, Beijing, China.
- Senior Department of General Surgery, Chinese PLA General Hospital, Beijing, China.
- Senior Department of General Surgery, Chinese PLA General Hospital, Beijing, China wubin@pumch.cn dujunfeng@301hospital.com.cn duxiaohui301@sina.com.
- The Seventh Medical Center, Chinese PLA General Hospital, Beijing, China wubin@pumch.cn dujunfeng@301hospital.com.cn duxiaohui301@sina.com.
- Department of General Surgery, Peking Union Medical College Hospital, Beijing, China wubin@pumch.cn dujunfeng@301hospital.com.cn duxiaohui301@sina.com.
Zitieren
APA
Wang, Q., Tian, N., Guo, H., Xiang, Y., Xiao, Y., Lin, G., Zhang, G., Xu, L., Lu, J., Chen, G., Cai, H., Du, X., Du, J., & Wu, B. (2026). Tumor stroma-immune interactions shape the immunosuppressive microenvironment and predict response to neoadjuvant chemoradiotherapy plus immunotherapy in rectal cancer. Journal for ImmunoTherapy of Cancer, 14(8), e015376. https://doi.org/10.1136/jitc-2026-015376
Vancouver
Wang Q, Tian N, Guo H, Xiang Y, Xiao Y, Lin G, et al. Tumor stroma-immune interactions shape the immunosuppressive microenvironment and predict response to neoadjuvant chemoradiotherapy plus immunotherapy in rectal cancer. Journal for ImmunoTherapy of Cancer. 2026;14(8):e015376. doi:10.1136/jitc-2026-015376
BibTeX
@article{Wang2026,
author = {Wang, Qianyu and Tian, Na and Guo, Hanchuan and Xiang, Yingshi and Xiao, Yi and Lin, Guole and Zhang, Guannan and Xu, Lai and Lu, Junyang and Chen, Gang and Cai, Huiyun and Du, Xiaohui and Du, Junfeng and Wu, Bin},
title = {Tumor stroma-immune interactions shape the immunosuppressive microenvironment and predict response to neoadjuvant chemoradiotherapy plus immunotherapy in rectal cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {8},
pages = {e015376},
doi = {10.1136/jitc-2026-015376}
}
EUVIMED